This article was highlighted for PRO subscribers, Seeking Alpha’s service for professional investors. Find out how you can get the best content on Seeking Alpha here.
Aurinia Pharmaceuticals (AUPH) is a Canadian drug company which has recently received expedited FDA review for its lupus nephritis ("LN") treatment Voclosporin. The company announced the details on July 21, 2020 (with my emphasis):
On July 21, 2020, the Company announced that the FDA has accepted the filing of its NDA for voclosporin, as a potential treatment for LN, a serious inflammation of the kidneys caused